Published • loading... • Updated
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Rare Disease growth and Azstarys integration lifted revenue, while management lifted 2026 sales and EBITDA targets after stronger Cortrophin Gel demand.
Summary by Seeking Alpha
5 Articles
5 Articles
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals…
Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation
DEER PARK, Illinois, August 14, 2026, 11:47 EDT — U.S. cash markets were open. Eton shares jumped 38.2% after quarterly revenue beat consensus by 38.7%.The company lifted its 2026 revenue floor by $25 million, to $145 million.The rally added about $427 million of equity value, a preliminary calculation. Eton Pharmaceuticals (NASDAQ:ETON) surged to a record…
Coverage Details
Total News Sources5
Leaning Left1Leaning Right2Center0Last UpdatedBias Distribution67% Right
Bias Distribution
- 67% of the sources lean Right
67% Right
L 33%
R 67%
Factuality
To view factuality data please Upgrade to Premium
